PharmiWeb.com - Global Pharma News & Resources
29-Jan-2025

Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth

  • Chiesi Group appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi to further enhance Board capabilities and internationalize leadership
  • These senior business leaders bring diverse expertise and international experience, strengthening governance and international best practices, whilst supporting Chiesi's global ambitions
  • New committees established: Governance, Nomination and Compensation; Audit and Risk; Strategy, Sustainability and Innovation

Parma, January 29th, 2025 – Chiesi, the international research-focused biopharmaceutical Group, announces the appointment of three new independent Non-Executive Directors (NEDs) to its Board: Roch Doliveux, Paolo Pucci and Daphne Quimi. Following a global search, the new Board members have joined the current five at Chiesi, effective January 28th, 2025.

The addition of three new NEDs is a significant part of Chiesi's broader strategy to enhance the Board’s capabilities, focusing on both upskilling and further internationalizing its leadership.

Driven by the continued foresight of the Chiesi family, this step represents a clear advancement in the company's efforts to enrich corporate governance as part of its ongoing international and patient impact growth. The new NEDs bring valuable expertise that will guide the company towards industry best practices.

By fostering diversity and introducing new competencies, they will support Chiesi’s commitment to sustainable growth, organizational transition, and international expansion, including into the important US market.

Furthermore, with the inclusion of these new members, Chiesi has also improved its Board functionality, particularly through the establishment of internal committees designed to enhance decision-making processes. The new committees are set up as follows:

  • Governance, Nomination and Compensation Committee: Roch Doliveux (Chairperson), Maria Paola Chiesi, Daphne Quimi, Alessandro Chiesi
  • Audit and Risk Committee: Daphne Quimi (Chairperson), Giacomo Chiesi, Paolo Pucci, Andrea Chiesi
  • Strategy, Sustainability and Innovation Committee: Paolo Pucci (Chairperson), Maria Paola Chiesi, Roch Doliveux, Andrea Chiesi

Each of the new Board members brings extensive experience to support Chiesi adapt to the rapidly evolving marketplace and continue its evolution:

Roch Doliveux has extensive leadership experience in Biopharmaceuticals and was CEO of UCB for ten years. He chairs the Boards of Pierre Fabre SA and Oxford Biomedica.

Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ArQule, leading it until its acquisition by Merck & Co. in 2020, and he held senior roles at Bayer Schering Pharma. He serves on the Boards of Replimune Group, Merus and West Pharmaceutical Services.

Daphne Quimi has made significant contributions to the pharmaceutical industry.  As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. She also held senior roles at Johnson & Johnson, Bristol-Myers Squibb and Avon. She serves on the Boards of Amylyx Pharmaceuticals and Century Therapeutics.

“We are thrilled to welcome Roch Doliveux, Paolo Pucci, and Daphne Quimi to our Board”, says Alessandro Chiesi, Chair. “Their experiences will enhance Chiesi’s governance and support our global ambitions. In line with our family’s vision, this move further reflects our commitment to constant improvement, and will allow us to even better focus on the strategic drivers of our company. It will benefit the Group as we continue to grow and internationalize, and we look forward to the positive impact they will bring.”

“I am confident Roch, Paolo, and Daphne will be excellent additions to the Chiesi Board,” says Giuseppe Accogli, CEO. “They all bring extensive international experience and diverse expertise, which will enhance our competitiveness. Their fresh perspectives and valuable skills will enrich our Board discussions, and strengthen our governance framework, which will help to unlock our potential to improve and develop as a company.”

Editor Details

Last Updated: 29-Jan-2025